… OS between the 2 groups, although carboplatin-pemetrexed treatment showed a statistically
significant PFS advantage over single-agent docetaxel. A substantial proportion of patients …

… During the time our trial was being conducted, results were reported from an ECOG
randomized phase 3 trial comparing single-agent pemetrexed with pemetrexed and carboplatin in …

… years, where maintenance pemetrexed was well tolerated … phase III study of elderly patients
(age 75–88) in which advanced NSCLC patients who received carboplatin plus pemetrexed …

… Chemotherapy with pemetrexed plus carboplatin followed by pemetrexed maintenance therapy
is … This phase II clinical study investigated the efficacy and safety of this regimen in older …

… (CBDCA, area under the curve = 5) plus pemetrexed (PEM, 500 … We conducted a multicenter
phase II trial to evaluate the efficacy … Currently, single-agent chemotherapy is used as the …

… At the time of this study, single-agent docetaxel had already … Single agent Alimta in poor
performance status in non-small … Randomized phase II trial of paclitaxel plus carboplatin or …

… Single agent maintenance therapy is widely accepted for advanced non-… randomised
phase II study, we evaluated the efficacy and safety of maintenance therapy with pemetrexed …

… standard adenocarcinoma regimen (pemetrexed carboplatin induction followed by maintenance
pemetrexed) and patients from Indian subcontinent. Hence, this study was carried out in …

… This randomized phase II trial was undertaken to evaluate the efficacy and safety of apatorsen
when added to a standard carboplatin/pemetrexed regimen in the first‐line treatment of …

… -center randomized phase II trial to compare the clinical outcomes between pemetrexed
plus … Our results suggest that single-agent pemetrexed might be another treatment option for …